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Through the combined use of 18F-fallypride positron emission tomography and magnetic resonance imaging this study examined
the neural mechanisms underlying the attentional deficits associated with attention deficit/hyperactivity disorder and their
potential reversal with a single therapeutic dose of methylphenidate. Sixteen adult patients with attention deficit/hyperactivity
disorder and 16 matched healthy control subjects were positron emission tomography and magnetic resonance imaging scanned
and tested on a computerized sustained attention task after oral methylphenidate (0.5 mg/kg) and placebo administration in a
within-subject, double-blind, cross-over design. Although patients with attention deficit/hyperactivity disorder as a group
showed significant attentional deficits and reduced grey matter volume in fronto-striato-cerebellar and limbic networks, they
had equivalent D2/D3 receptor availability and equivalent increases in endogenous dopamine after methylphenidate treatment to
that observed in healthy control subjects. However, poor attentional performers drawn from both the attention deficit/hyper-
activity disorder and the control groups had significantly reduced left caudate dopamine activity. Methylphenidate significantly
increased dopamine levels in all nigro-striatal regions, thereby normalizing dopamine levels in the left caudate in low per-
formers. Behaviourally, methylphenidate improved sustained attention in a baseline performance-dependent manner, irrespective
of diagnosis. This finding was accompanied by an equally performance-dependent effect of the drug on dopamine release in the
midbrain, whereby low performers showed reduced dopamine release in this region. Collectively, these findings support a
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dimensional model of attentional deficits and underlying nigro-striatal dopaminergic mechanisms of attention deficit/hyper-
activity disorder that extends into the healthy population. Moreover, they confer midbrain dopamine autoreceptors a hitherto
neglected role in the therapeutic effects of oral methylphenidate in attention deficit/hyperactivity disorder. The absence of
significant case–control differences in D2/D3 receptor availability (despite the observed relationships between dopamine activity
and attention) suggests that dopamine dysregulation per se is unlikely to be the primary cause underlying attention deficit/
hyperactivity disorder pathology in adults. This conclusion is reinforced by evidence of neuroanatomical changes in the same set
of patients with attention deficit/hyperactivity disorder.
Keywords: attention deficit/hyperactivity disorder; 18F-fallypride PET; dopamine; methylphenidate; sustained attention
Abbreviations: AC–PC = anterior commissure–posterior commissure; ADHD = attention deficit/hyperactivity disorder;
BPND =
18F-fallypride binding potential; DSM = Diagnostic and Statistical Manual of Mental Disorders; MRAC-PC = scans manually
aligned to the anterior commissure-posterior commissure line; RVP = Rapid Visual Information Processing
Introduction
Attention deficit/hyperactivity disorder (ADHD) is a neurodevelop-
mental disorder characterized by symptoms of inattention and/or
hyperactivity/impulsivity. Despite its declining prevalence with age,
ADHD symptoms in some affected patients persist into adulthood,
affecting 2.5% of the adult population (Simon et al., 2009). The
clinical effectiveness of stimulants such as methylphenidate in the
treatment of ADHD suggests a putative role for both dopamine
and noradrenaline in the manifestation of the disorder (Castells
et al., 2011). However, despite decades of genetic, clinical and neu-
roimaging research, the precise neurobiological mechanisms under-
lying the disorder and its treatment remain poorly understood.
Long-standing cognitive theories of ADHD postulate a defi-
ciency in top–down cognitive control processes underpinning at-
tention and executive function deficits (Barkley, 1997; Nigg, 2000;
Bush et al., 2005; Kuntsi et al., 2006; Paloyelis et al., 2007 for
review see Del Campo et al., 2012). Providing support to these
theories, one of the best replicated findings in ADHD is that of
reduced grey matter volume in the catecholamine-rich fronto-
striato-cerebellar circuits known to subserve these cognitive func-
tions (Seidman et al., 2005; Nakao et al., 2011). Notwithstanding
the growing evidence on fronto-striatal dysfunction and the effi-
cacy of stimulant drugs in the clinical management of patients
with ADHD, the precise role of dopamine in the pathophysiology
of the disorder is still unclear. Indeed, in vivo nuclear imaging
techniques such as PET and single photon emission computed
tomography (SPECT) have often yielded inconsistent findings re-
garding the state of the dopamine system in this patient popula-
tion (Del Campo et al., 2011a). A recent set of case–control PET
studies in adult medication-naı¨ve patients found that ADHD is
associated with reduced dopamine transporter and dopamine
D2/D3 receptor availability in selected brain regions of the left
hemisphere, including the nucleus accumbens, caudate and mid-
brain (Volkow et al., 2007a, b, 2009). Although these impressive
studies had substantial numbers of patients, there was consider-
able overlap with the control population in terms of both dopa-
mine receptor and transporter availabilities, implying that the
diagnostic utility of these markers is limited.
The binding competition between D2/D3 receptor radioligands
and endogenous dopamine allows measuring changes in
dopamine levels following a pharmacological challenge, for ex-
ample a psychostimulant. Acute administration of methylphenidate
would be expected to increase endogenous dopamine, leading to
a reduction of D2/D3 receptor radioligand binding through com-
petitive displacement. To date there are two studies that have
used this imaging paradigm to examine the endogenous tone of
the dopamine system in patients with ADHD. One study in ado-
lescent patients with ADHD found that oral methylphenidate-
induced increases in dopamine concentrations in the right striatum
were greater in patients showing poor performance on a compu-
terized continuous performance test relative to high performing
patients (Rosa-Neto et al., 2005). A subsequent study of intraven-
ous methylphenidate effects in adult patients with ADHD showed
blunted dopamine responses to methylphenidate in the caudate in
patients compared with control subjects, although there was no
concurrent objective measure of cognitive performance (Volkow
et al., 2007b).
Although it is possible that the state of the striatal dopamine
system changes with age in ADHD, in this dopamine receptor PET
imaging study we sought to resolve the above discrepancy by
investigating the effects of oral methylphenidate on both en-
dogenous dopamine levels and sustained attention in adult pa-
tients with ADHD compared with healthy matched control
subjects using a within-subject, counter-balanced placebo-
controlled design. High resolution MRI scans were also acquired
and analysed for case–control differences in grey matter volume to
allow, for the first time in the ADHD literature, the interpretation
of the PET results in the light of potential brain tissue abnormal-
ities. The full set of MRI data, including also diffusion tensor ima-
ging data, will be reported in more detail elsewhere.
As a methodological innovation, which further distinguishes the
current study from previous ones, we used the co-registered high
resolution magnetic resonance images to accurately localize PET
signals within the striatum and the midbrain. We employed a
model of functional rather than purely anatomical subdivisions of
the striatum (Haber et al., 2000) that has been increasingly used
to optimize the analysis of PET studies (Kegeles et al., 2010). This
model is based on evidence that cortico-striatal networks follow a
ventro-medial to dorsolateral gradient, with activity along this
gradient modulating limbic, cognitive and motor processing
(Martinez et al., 2003). Through its connections with the striatum,
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the midbrain operates as an interface for the dynamic processing
of striatal function. According to preclinical evidence, stimulant-
induced increases in endogenous dopamine levels trigger negative
feedback mechanisms that inhibit dopamine neuron firing
(Bunney and Achajanian, 1976). These negative feedback mech-
anisms are mediated by somato-dendritic D2/D3 autoreceptors
located on midbrain dopamine neurons, which play a key role
in regulating dopamine synthesis and release by acting as potent
inhibitors in the presence of high dopamine concentrations
(Mercuri et al., 1992, 1997; Sesack et al., 1994; Khan et al.,
1998). How the therapeutic effects of methylphenidate might
depend on the afferent control of midbrain dopamine neurons
has been unexplored to date. This question is particularly relevant
because findings for both juvenile and adult ADHD have impli-
cated functional and structural midbrain abnormalities in the
pathophysiology of the disorder (Ernst et al., 1999; Jucaite
et al., 2005; Volkow et al., 2009; Romanos et al., 2010),
also consistent with experimental animal models of ADHD (Leo
et al., 2003).
To investigate nigro-striatal mechanisms underlying ADHD and
its treatment with methylphenidate, we used PET imaging of
18F-fallypride, which has a higher affinity than 11C-raclopride
(the radioligand of choice in all previous dopamine receptor ima-
ging studies in ADHD) and is thus better suited for simultaneous
measurement of D2/D3 receptor availability in striatal regions and
the midbrain (Riccardi et al., 2006a, b; Cropley et al., 2008;
Slifstein et al., 2010). Through estimation of non-displaceable
18F-fallypride binding potential (BPND), the following questions re-
garding the neurochemical underpinnings of ADHD were
addressed.
First, do patients with ADHD have reduced D2/D3 receptor
availability in the striatum and the midbrain compared with
healthy volunteers? Second, how is D2/D3 receptor availability in
these regions associated with inattention, a core feature of the
disorder (Biederman et al., 2000; Nigg, 2005)? Third, how does
a therapeutic oral dose of methylphenidate affect D2/D3 receptor
availability in the striatum and the midbrain?, and fourth, how are
the effects on receptor availability related to drug-induced
changes on performance on a task of sustained attention previ-
ously reported to be sensitive to single oral doses of this drug
(Turner et al., 2005)? Finally, are the observed drug effects on
receptor availability quantitatively different in patients with ADHD
and healthy volunteers?
The latter question is especially topical (Sahakian and Morein-
Zamir, 2007) because methylphenidate has been reported to aug-
ment several aspects of cognition in healthy subjects (Rapoport
et al., 1978, 1980; Strauss et al., 1984; Koelega, 1993; Elliott
et al., 1997; Mehta et al., 2000) similar to those improved in
ADHD (Mehta et al., 2004; Turner et al., 2005; Clark et al.,
2007; Spencer et al., 2007). The effects of methylphenidate and
related stimulant drugs in healthy individuals have been shown to
be baseline-dependent; i.e. those subjects with relatively low per-
formance levels exhibit greater benefit after the drug (Naylor
et al., 1985; Rogers et al., 1999; Mehta et al., 2000; Turner
et al., 2003; Clatworthy et al., 2009). These findings can be in-
terpreted in the light of a hypothesized inverted U-shaped func-
tion relating dopamine and noradrenaline activity to performance
(Robbins and Sahakian, 1979). Of course, it is also possible that
the cognitive enhancing effects in patients may similarly be de-
pendent on baseline-dependent considerations.
According to previous reports of altered brain tissue volume and
dysregulated dopamine neurotransmission in ADHD, we hypothe-
sized that patients with ADHD would show reduced grey matter
volume and D2/D3 receptor availability in selected brain regions
involved in dopamine-modulated circuits (Volkow et al., 2007b,
2009). We also hypothesized that methylphenidate would increase
endogenous dopamine levels in both ADHD and healthy control
subjects, improving attention in patients with ADHD and possibly
also in some healthy volunteers as a function of baseline perform-
ance. In accordance with previous evidence linking abnormalities
in the left caudate with attentional deficits, we expected dopamine
dysregulation in this region to be specifically associated with im-
paired sustained attention on the computerized cognitive test.
Materials and methods
Subjects
Sixteen male adult patients with ADHD and 16 control subjects
matched for gender, age and IQ were enrolled in the study after
meeting inclusion criteria and providing written informed consent.
The study was approved by the Cambridge Research Ethics
Committee, The UK Administration of Radioactive Substances
Advisory Committee and was formally exempted from clinical trial
status by the UK Medicines and Healthcare Regulatory Agency.
Patients were recruited from the Adult ADHD Research Clinic
Cambridge and through the Attention Deficit Disorder Information
and Support Service (ADDISS), UK. Diagnosis was contingent upon
six of nine DSM-IV (Diagnostic and Statistical Manual of Mental
Disorders, fourth edition) inattention and/or hyperactivity/impulsivity
criteria being met during childhood and the previous 6 months (1994).
Clinical assessments were performed by two psychiatrists specialized in
adult ADHD (J.D., U.M.) as described previously (Chamberlain et al.,
2007). Of the 16 patients, 15 met criteria for ‘combined type’ and one
for ‘inattentive type’. Seven patients had a history of prescribed medi-
cation with methylphenidate, and one had previously been exposed to
atomoxetine through participation in a past research study. The re-
maining patients (n = 8) were ADHD medication-naı¨ve. Patients on
methylphenidate treatment at the time of scanning were asked to
discontinue their medication at least 3 days before each PET session.
All participants underwent an extended clinical interview using the
Mini International Neuropsychiatric Inventory (MINI) (Sheehan et al.,
2010). Exclusion criteria were the presence of axis-I disorders or any
major neurological or internal disease, left handedness, verbal IQ 590
[National Adult Reading Test (NART)] (Nelson, 1982) and current cig-
arette smoking and/or drug abuse, as controlled by urine screening
(Euromed, Drug Screen Card DOA-154-731, 5072KAB). Participants
were asked to abstain from drinking alcoholic or caffeine-containing
drinks for 12 h before each testing session.
Experimental design and cognitive
assessment
Participants were enrolled into a randomized, double-blind placebo-
controlled cross-over design, consisting of two 18F-fallypride PET
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scans at least a week apart and one MRI scan. On each PET session,
subjects were administered a capsule containing either 0.5 mg/kg of
methylphenidate or placebo 75 min before the 18F-fallypride injection
(Fig. 1). The dose of 0.5 mg/kg was chosen to be within the thera-
peutic range used in the clinic: according to the NICE 2008 guidelines
regarding the diagnosis and treatment of patients with ADHD, starting
methylphenidate doses of 3  5 mg or 3  10 mg and a dose limit of
100 mg per day are recommended. A dose of 0.5 mg/kg equals 40 mg
for an 80 kg patient, representing thus a medium dose for a single
dose study. At 0, 2 and 4 h after capsule administration, blood samples
were collected for determination of methylphenidate plasma concen-
trations (Supplementary material) to assess compliance with drug dis-
continuation in medicated patients and account for between-subject
differences in methylphenidate plasma levels. Cardiovascular measures
were regularly monitored throughout the study.
On both PET sessions, participants performed the Rapid Visual
Information Processing (RVP) task from CANTAB (Cambridge
Automated Neuropsychological Testing Battery, www.camcog.com).
RVP primarily measures sustained attention, defined as the ability to
maintain attention on a series of numerical stimuli over a period of
time, to detect infrequent targets (Coull et al., 1996). The task was ad-
ministered during a scanning break 2.5 h after capsule intake (Fig. 1),
coinciding with the estimated peak effectiveness of methylphenidate
(Challman and Lipsky, 2000). Performance on the RVP task was mea-
sured by the non-parametric signal detection parameter A’ (discriminative
sensitivity) (McNicol, 1972). The selection of RVP A’ to measure atten-
tional performance in this study is supported by evidence that this par-
ameter (i) is a suitable ADHD endophenotype (Gau and Huang, 2013); (ii)
is associated with activity in neural networks including frontal and striatal
regions (Lawrence et al., 2003); and (iii) is sensitive to the enhancing
effects of drugs known to be effective in ADHD, previously reported in
both patients with ADHD (Turner et al., 2005) and healthy control sub-
jects (Crockett et al., 2010; Supplementary material). Response latencies
were also measured. To minimize practice effects, all subjects performed
the task once before their first study session.
All participants completed the adult ADHD self-rating scale (v1.1), a
short self-rating test addressing the severity of ADHD symptoms in
adults consistent with DSM-IV criteria (Kessler et al., 2005).
Imaging
Magnetic resonance acquisition
Magnetic resonance images were acquired for all subjects on a
Siemens Trio 3 T system (Siemens Medical Systems) with gradient
coils capable of 45 mT/m and 200 T/m/s slew rate. A 12-channel
total-imaging matrix head-coil was used to transmit/receive radio-
frequency magnetic resonance signals. T1-weighted anatomical scans
were acquired using a 3D MP-RAGE pulse sequence with the
following parameters: repetition time/echo time/inversion
time = 2300 ms/2.98 ms/900 ms, flip angle 9, 176 slices, 256  256
matrix size, 1  1  1 mm3 voxel size, echo spacing = 7.1 ms,
bandwidth = 240 Hz per pixel. Images were manually aligned to the
anterior commissure (AC) – posterior commissure (PC) line. A T2-
weighted image was also acquired for each subject (echo
time = 104 ms, 27 slices, 0.7  0.7  4 mm3 voxel size).
Positron emission tomography acquisition
18F-fallypride PET data were acquired in 3D mode on a GE Advance
scanner (General Electric Medical Systems). Before 18F-fallypride injec-
tion, a 15 min transmission scan was acquired. 18F-fallypride was in-
jected intravenously over 30 s, with a mean activity of 103.5 MBq
(range: 52.2–119.8 MBq), and a fallypride mass of 1.3  0.7 nmols.
From the start of the 18F-fallypride injection PET emission data were
continuously acquired for 75 min in 55 frames (Fig. 1). After a 30 min
break, subjects were repositioned in the scanner and after another
15-min transmission scan, a second set of 18F-fallypride data were
acquired over the next hour. Images were reconstructed using the
PROMIS 3D filtered back-projection algorithm (Kinahan and Rogers,
1989) into 2.34  2.34  4.25 mm voxels.
Magnetic resonance imaging preprocessing and grey
matter volume analysis
All MPRAGE scans were manually aligned to the AC–PC line
(MRAC-PC). Before analysis, volumes were preprocessed, and then spa-
tially normalized and segmented into grey and white matter tissue
using the unified segmentation model in SPM5 (Ashburner and
Friston, 2005). Statistical case–control differences in tissue volume
were assessed through a non-parametric, permutation inference
method using Cambridge Brain Analysis v1.3.2 (CAMBA; http://
www-bmu.psychiatry.cam.ac.uk/software/) (Bullmore et al., 1999).
This methodology confers a number of advantages, notably the en-
hancement of sensitivity and the control for type I errors. For each
between-group comparison, the statistical threshold of 5 0.05 was
applied. Results were corrected for multiple comparisons by controlling
the family-wise error rate and setting the number of false positive
clusters expected under the null hypothesis to 51. Clusters showing
significant between-group differences were described in terms of the
Automated Anatomical Labelling (AAL) template image (where voxels/
region4 20) (Tzourio-Mazoyer et al., 2002).
Positron emission tomography realignment and
co-registration to magnetic resonance imaging
Images from each PET scan were realigned and co-registered to the
MRAC-PC using SPM2 (www.fil.ion.ucl.ac.uk/spm) as previously
described (Del Campo et al., 2011b).
18F-fallypride
injection
60 min                               75 min                 30 min                  60 min
Emission (part 2)Emission (part 1)
MPH (0.5 mg/kg)
or placebo
RVP
Figure 1 Time line for PET and RVP data acquisition after capsule administration. Grey boxes indicate 15 min transmission scans.
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Region of interest delineation
For each subject, regions of interest were manually drawn on coronal
planes of the MRAC-PC with Analyze 7.0 (AnalyzeDirect) as previously
described (Mawlawi et al., 2001; Martinez et al., 2003; Del Campo
et al., 2011b). The following striatal subregions were defined bilat-
erally: ventral striatum, pre-commissural dorsal putamen, pre-commis-
sural dorsal caudate, post-commissural putamen and post-commissural
caudate (Fig. 2).
These subregions allowed classification of the striatum into the fol-
lowing functional modules: ventral striatum; associative striatum, com-
prising pre-commissural dorsal caudate, post-commissural caudate and
pre-commissural dorsal putamen and sensorimotor striatum, consisting
of the post-commissural putamen (Haber et al., 2000; Joel and
Weiner, 2000; Haber, 2003). Evidence suggests that through their
involvement in different cortico-striatal networks, these modules are
functionally distinct, with the ventral striatum being implicated in
emotion, motivation and reward-guided behaviours, the associative
striatum in cognition, and the sensorimotor striatum in motor function
(Martinez et al., 2003). The aggregate of bilateral ventral striatum,
associative striatum and sensorimotor striatum is henceforth referred
to as total striatum.
Bilateral midbrain regions of interest including the substantia nigra
and the ventral tegmental area were delineated on transverse planes
of the MRAC-PC-coregistered T2-weighted image as described else-
where (Foster et al., 2008). To allow BPND values to be calculated
using reference tissue modelling, a bilateral cerebellar region was
drawn on the MRAC-PC.
Regional quantification of binding potential
Regional BPND was estimated by fitting the simplified reference tissue
model (Gunn et al., 1997) to region of interest time activity curves.
The cerebellar time activity curve between 75–120 min post-injection
was estimated by fitting an exponential function from 50 min onwards.
To calculate mean BPND for associative striatum, bilateral regions and
total striatum, BPND values for the constituent regions of interest were
weighted in proportion to region of interest volume. Changes in re-
ceptor availability following methylphenidate relative to placebo were
estimated by BPND % change:
BPND%change ¼ 100  ½BPNDðmethylphenidateÞ
BPNDðplaceboÞ=BPNDðplaceboÞ
ð1Þ
Statistical analysis
Group effects on ADHD self-rating scale scores and both group and
methylphenidate effects on task performance and BPND were tested
using univariate and repeated measures analysis of variance (ANOVAs)
with group and medication status as between-subject factors. Where
assumptions of sphericity were violated, degrees of freedom were
corrected by applying Greenhouse-Geisser corrections. Significant
differences were further examined using post hoc t-tests or, where
appropriate, the equivalent versions for non-parametric data
(Wilcoxon signed-rank test and Mann-Whitney U test).
Pearson correlations and where appropriate Spearman’s rank correl-
ations were used to describe relationships between non-imaging
C 
BA
Figure 2 (A and B) Coronal planes through an AC–PC aligned MPRAGE image showing striatal regions of interest. (A) Ventral striatum
(2, 3), pre-commissural dorsal putamen (4, 5), pre-commissural dorsal caudate (6, 7); (B) post-commissural putamen (8, 9) and
post-commissural caudate (10, 11). The red line helped to divide the pre-commissural caudate and putamen into ventral and dorsal.
(C) Midbrain region of interest defined on a T2 scan co-registered to the MRAC-PC.
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measures and both BPND and BPND % change. Where relevant, me-
thylphenidate plasma concentrations were partialled out. Relationships
were investigated for left and right hemispheres separately, in-line with
previous observations of lateralization differences in dopaminergic par-
ameters in the healthy population (Larisch et al., 1998; Vernaleken
et al., 2007) as well as in patients with ADHD (Volkow et al.,
2007a, b, 2009). To allow assessment of group differences, correlation
coefficients were transformed into z-scores. To control for the overall
type 1 error rate, stepwise linear regression models were also used to
establish the relative contributions of 18F-fallypride BPND to attentional
performance variability, both at baseline and following methyl-
phenidate. BPND measures of all regions of interest were entered
into the models. An alpha level of 0.05 was chosen as the statistical
threshold.
Results
Sample characteristics and cognitive
performance
Demographic characteristics of the sample and mean scores on
psychological measures are shown in Table 1. Both groups were
matched for age and IQ. Patients with ADHD had significantly
higher ADHD self-rating scale scores (P40.01) and performed
significantly worse on the RVP A’ signal detection parameter
[main effect of group: F(1,29) = 8.31, P = 0.007; placebo data
only: F(1,29) = 9.89, P = 0.004]. There were no between session
practice effects on task performance (P40.1).
Grey matter volume
No group differences were found in total intracranial volume and
total grey matter volume (P4 0.1). However, patients with ADHD
showed significantly reduced grey matter volume in left prefrontal
cortical areas (middle frontal cortex, inferior portions of the orbi-
tofrontal cortex and gyrus rectus), and in bilateral putamen, amyg-
dala, hippocampus, fusiform, insula and cerebellum (Table 2 and
Fig. 3).
For clarity, regional PET and behavioural results (and the rela-
tionship between both) are subsequently presented split by experi-
mental session (placebo then methylphenidate). Supporting
whole-brain voxel-wise PET results are presented and discussed
in the Supplementary material.
Placebo results
Regional analysis of BPND on placebo
The mean BPND values were not significantly different between
patients with ADHD and control subjects across all regions
(either unilaterally or bilaterally), with bilateral values for the
latter shown in Fig. 4. Regional BPND values pooled across all
subjects are shown in Table 3. BPND values on placebo were in
the same range as those previously reported in a study examining
test–retest variability of baseline 18F-fallypride BPND across the
same brain regions (Cropley et al., 2008) (Supplementary
material).
Relationship between ADHD self-rating scale and
regional BPND on placebo
ADHD self-rating scale total and inattention sub-scores correlated
negatively with total striatum BPND both in patients (r = 0.48,
P = 0.032; r = 0.51, P = 0.020) and control subjects (r = 0.47,
P = 0.04; r = 0.54, P = 0.019) (Fig. 5A) but did not correlate
with BPND in substantia nigra/ventral tegmental area for either
subject group. Conversely, self-rated hyperactivity was not asso-
ciated with BPND in total striatum but was negatively correlated
with BPND in substantia nigra/ventral tegmental area in control
subjects (r = 0.59, P = 0.010) although not in patients
(r = 0.123, P = 0.33) (Fig. 5B).
Correlation coefficients for left and right striatal subregions and
substantia nigra/ventral tegmental area were similar in patients
and control subjects (P40.1). For patients and control subjects
combined, inattention scores were negatively correlated with BPND
in the portions of the associative striatum corresponding to pre-
commissural dorsal caudate and post-commissural caudate
(r = 0.393, P = 0.014; r = 0.375, P = 0.019) and in sensori-
motor striatum (r = 0.324, P = 0.038). Hyperactivity scores for
all subjects on the other hand were associated with BPND in left
substantia nigra/ventral tegmental area (r = 0.34, P = 0.032) but
not in any other region.
Table 1 Subject characteristics
ADHD patients (n = 16) Controls (n = 16) F-value P-value
Age, years 30.3 (7.4) 28.9 (6.0) 0.3 0.57
NART 112.0 (9.2) 115.7 (4.4) 2.1 0.16
Adult Self Report Scale
Total 54.1 (7.9) 25.9 (6.7) 68.4 _0.001
Inattention 28.1 (4.8) 14.5 (3.6) 48.3 _0.001
Hyperactivity 26.1 (4.8) 11.4 (4.8) 43.1 _0.001
RVP performance on placebo
A’ 0.92 (0.05) 0.97 (0.03) 9.9 0.004
Mean latency, ms 424 (59) 373 (40) 3.0 0.09
Values are mean (SD).
NART = National Adult Reading Test.
Group comparisons were carried out using ANOVAs, significant P-values (50.05) are in bold.
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Table 2 Regions of decreased grey matter density in ADHD patients compared with controls
Cluster Region name (AAL) Location of peak
(x, y, z) [mm]
Voxels F
GM 1 503 vox Cerebellum crus II R 40 66 48 35 3.86
Cerebellum VIIB R 38 66 48 70 3.79
Cerebellum VIII R 22 74 48 392 3.66
GM 2 2089 vox Superior frontal gyrus (orbital portion) L 16 16 20 55 3.29
Inferior frontal gyrus (pars triangularis) L 40 26 2 71 4.11
Inferior frontal orbital gyrus L 26 32 12 64 3.51
Olfactory cortex L 12 8 18 49 3.76
Gyrus rectus L 6 38 20 65 4.16
Insula L 38 0 8 127 3.80
Hippocampus L 22 12 12 297 4.59
Parahippocampal gyrus L 28 24 24 133 3.74
Amygdala L 26 4 14 81 3.78
Fusiform gyrus L 28 30 20 173 3.86
Putamen L 28 2 6 92 3.51
Middle temporal gyrus L 46 2 16 57 4.39
Inferior temporal gyrus L 38 20 28 23 2.54
Cerebellum IV, V L 14 54 24 184 3.11
Cerebellum VI L 14 58 24 213 3.52
Vermis IV, V 2 60 14 23 2.55
GM 3 692 vox Hippocampus R 30 30 10 107 3.36
Parahippocampal gyrus R 26 34 12 106 3.31
Lingual gyrus R 28 48 6 28 3.42
Fusiform gyrus R 38 22 26 106 4.05
Cerebellum IV, V R 26 38 24 166 4.25
Cerebellum VI R 36 46 32 144 3.57
GM 4 749 vox Insula R 40 8 2 114 3.43
Hippocampus R 34 6 18 56 5.51
Amygdala R 30 4 18 79 4.04
Putamen R 34 2 6 202 3.89
GM 5 197 vox Middle frontal gyrus 28 40 20 231 6.53
Regional labels are clusters of the Automated Anatomical Labelling (AAL). Locations are in the stereotactic space of the MNI. Cluster peaks are highlighted in bold.
GM = grey matter.
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Figure 4 Regional variation in 18F-fallypride binding potential
(BPND) on placebo in healthy control subjects and ADHD
patients. Error bars denote standard error of the mean.
VST = ventral striatum; AST = associative striatum; prePUT =
pre-commissural putamen; preCAU = pre-commissural caudate;
postCAU = post-commissural caudate; SMST = sensorimotor
striatum; SN/VTA = substantia nigra/ventral tegmental area.
Figure 3 Cluster of greatest grey matter volume reduction in
patients with ADHD compared with control subjects located in
the left middle frontal gyrus, overlaid on a rendered standar-
dized brain template.
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Relationship between sustained attention (A’) and
regional BPND on placebo
In patients, low A’ scores were associated with low BPND in left
pre-commissural dorsal caudate (r = 0.48, P = 0.031) and right
post-commissural caudate (r = 0.43, P = 0.048). Although the cor-
relation coefficients in control subjects were not significant, they
were in the same direction as those observed in patients for all
regions and were not significantly different from them (P40.1).
Across the entire subject group, low A’ scores were associated
with low BPND in left pre-commissural dorsal caudate (r = 0.314,
P = 0.04) as well as in left and right post-commissural caudate
(r = 0.308, P = 0.043 and r = 0.323, P = 0.036, respectively;
mean: r = 0.33, P = 0.032).
Stepwise linear regression of all regional BPND values on atten-
tional performance (in all subjects) revealed a significant best-fit
model with the left pre-commissural dorsal caudate as independ-
ent variable [ = 0.386, P = 0.029; F(1,30) = 5.26, adjusted
R2 = 0.21].
Methylphenidate results
Plasma level analysis and cardiovascular effects of
methylphenidate
Plasma level analysis of methylphenidate confirmed randomization
and compliance with discontinuation of therapeutic medication.
Methylphenidate produced significant increases in systolic blood
pressure [mean paired difference 5 mmHg; t(31) = 4.5;
P50.001] and heart rate [mean paired difference 7 beats per
min; t(31) = 4.4; P50.001] (Supplementary material). Mean
Figure 5 Linear regressions and corresponding Pearson correlations between (A) adult ADHD self-rating scale (ASRS) inattention scores
and BPND in total striatum and (B) ADHD self-rating scale hyperactivity scores and BPND in the substantia nigra/ventral tegmental area
(SN/VTA) in patients with ADHD and control subjects.
Table 3 18F-fallypride BPND at baseline and after methylphenidate, pooled across all subjects
BPND (Placebo) BPND (MPH) BPND % change (MPH
relative to placebo)
Region Left Right Bilateral Left Right Bilateral Left Right Bilateral
Striatum 16.3 (1.6) 16.4 (1.6) 16.4 (1.6) 15.3 (1.4) 15.4 (1.5) 15.4 (1.5) 6.2 (5.8) 5.1 (5.9) 5.9 (5.5)
VST 15.3 (1.5) 14.9 (1.7) 15.1 (1.5) 14.4 (1.6) 14.5 (1.8) 14.5 (1.6) 5.6 (7.8) 2.2 (10.1) 4.0 (7.4)
AST 16.1 (1.8) 16.2 (1.8) 16.1 (1.8) 15.1 (1.6) 15.2 (1.6) 15.2 (1.6) 5.4 (7) 5.5 (5.5) 5.4 (5.9)
Pre-PUT 18.6 (2.1) 18.9 (2.1) 18.8 (2.0) 17.5 (1.8) 17.7 (1.9) 17.6 (1.8) 5.8 (7.5) 6.5 (6.1) 6.2 (5.9)
Pre-CAU 15.7 (2.0) 15.5 (1.8) 15.6 (1.8) 14.8 (1.7) 14.8 (1.7) 14.8 (1.7) 4.8 (7.5) 4.6 (6.3) 4.8 (6.2)
Post-CAU 9.9 (1.6) 9.9 (1.7) 9.9 (1.5) 9.2 (1.5) 9.3 (1.6) 9.2 (1.5) 6.4 (10) 5.6 (10.3) 6.1 (9.1)
SMST Post-PUT 17.8 (2.0) 17.9 (1.8) 17.9 (1.8) 16.4 (1.7) 16.5 (1.7) 16.5 (1.7) 7.5 (7.2) 7.7 (6.4) 7.6 (6.1)
SN/VTA 1.4 (0.2) 1.3 (0.2) 1.4 (0.2) 1.3 (0.2) 1.2 (0.2) 1.2 (0.2) 7.2 (10.5) 8.0 (11.0)a 7.8 (8.5)
Data are mean (SD).
AST = associative striatum; CAU = caudate; post = post-commissural; pre = pre-commissural; PUT = putamen; SMST = sensorimotor striatum; SN/VTA = substantia nigra/
ventral tegmental area; VST = ventral striatum.
Levels of significance of BPND % change were assessed with paired-samples t-tests and, where appropriate, with
a Wilcoxon Signed ranks test. BPND changes significant
below Bonferroni corrected level of P5 0.003 for left and right regions and P5 0.005 for bilateral regions are in bold.
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methylphenidate plasma concentrations were similar in patients
with ADHD and control subjects (P4 0.05).
Effects of methylphenidate on sustained attention
There was no significant main effect of methylphenidate on A’,
nor was there an interaction of methylphenidate with group.
Covarying for medication status within the patient groups did
not change these results (interactions between treatment and
group versus medication status all P40.05) (Fig. 6A).
Based on accumulating evidence that effects of methylphenid-
ate and related drugs on cognition are baseline performance-
dependent (Kimberg et al., 1997; Mattay et al., 2000; Mehta
et al., 2000; Gibbs and D’Esposito, 2005; Tipper et al., 2005;
Finke et al., 2010), changes in sustained attention following me-
thylphenidate were assessed as a function of baseline A’ scores,
independent of group. We thus split participants into high and low
performers based on the median for A’, as used previously
(Kimberg et al., 1997). There was an overlap of performance be-
tween patients with ADHD and control subjects in about a third of
all subjects. High and low performers were matched for age (mean
28  6 years versus 31  7 years; P = 0.17), IQ (mean 113  8
versus 115  7) and methylphenidate plasma concentrations
(mean 10  3.16 mg/l versus 9.87  3.78mg/l) (furthermore, four
of the five patients with ADHD assigned to the high performing
group were on prescribed ADHD medication).
This analysis showed that methylphenidate affected cognition
differentially in high and low performing subjects [drug by group
interaction: F(1,28) = 10.94, P = 0.003], improving A’ scores in
low [t(15) = 2.610, P = 0.02] but not in high performers
[t(15) = 1.656, P = 0.119] (Fig. 6B).
Effects of methylphenidate on regional BPND
Methylphenidate significantly reduced BPND [main effect of treat-
ment: F(1,29) = 30.51, P50.001], ranging from 4.0 to 7.8%
depending on anatomical region {region of interest by treatment
interaction [F(3,87) = 10.31, P50.001]}, being greatest in sub-
stantia nigra/ventral tegmental area and least in ventral striatum
(Table 3 and Fig. 7). Methylphenidate also reduced BPND differ-
entially across ventral striatum, associative striatum and sensori-
motor striatum [region of interest by treatment interaction:
F(2,42) = 8.34, P = 0.002], revealing a preferential effect in sen-
sorimotor striatum. The magnitude of regional BPND % change
was similar in patients with ADHD and control subjects (main
effect of group and group by drug interaction: P40.05).
Baseline performance-dependent relationship between
methylphenidate effects on sustained attention (A’ %
change) and BPND % change
Methylphenidate-induced % change in A’ was negatively corre-
lated with BPND % change in ventral striatum (r = 0.29,
P = 0.05) and positively with substantia nigra/ventral tegmental
area (r = 0.5, P = 0.002), with the correlation coefficients being
highly significantly different (z = 3.25, P50.001).
After controlling for between-subject differences in methylphen-
idate plasma levels, improvements in sustained attention were
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Figure 7 Methylphenidate (MPH)-induced BPND % change in
healthy control subjects and ADHD patients across regions of
interest. Reductions in BPND were significant in all regions and
similar in both groups. There was a trend for decreased BPND %
change in substantia nigra/ventral tegmental area in patients
with ADHD compared to control subjects [t(30) = 1.65,
P = 0.055]. Error bars denote standard error of the mean.
VST = ventral striatum; AST = associative striatum;
prePUT = pre-commissural putamen; preCAU = pre-commis-
sural caudate; postCAU = post-commissural caudate;
SMST = sensorimotor striatum; SN/VTA = substantia nigra/ven-
tral tegmental area.
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Figure 6 RVP A’ scores following placebo and methylphenidate
(MPH) as a function of (A) ADHD diagnosis, with the ADHD
group split by medication status and (B) baseline performance,
with the combined ADHD and control groups split by the
median of A’.
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associated with greater BPND % change in right ventral striatum
(r = 0.318, P = 0.043) and lower BPND % change in substantia
nigra/ventral tegmental area [r = 0.32, P = 0.043; r = 0.309,
8P = 0.048; r = 0.374, P = 0.021; in left, right and bilateral sub-
stantia nigra/ventral tegmental area, respectively (Fig. 8)].
Correlation coefficients for ventral striatum and substantia
nigra/ventral tegmental area were significantly different from
each other (P5 0.01), but similar in patients with ADHD and
control subjects.
The above analyses were also calculated after excluding ceiling
performers on the attentional task (five control subjects and one
patient), yielding similar results (Supplementary material).
We hypothesized that the relationship between A’ % change
and BPND % change for both ventral striatum and substantia
nigra/ventral tegmental area would be dependent on A’ baseline
scores, based on the aforementioned differential effect of methyl-
phenidate in high and low performers. Controlling for between-
subject differences in A’ scores (in addition to methylphenidate
plasma levels) had no impact on the correlation between methyl-
phenidate-induced changes in A’ scores and BPND % change in
ventral striatum (r = 0.348, P = 0.032 for bilateral ventral stri-
atum; r = 0.247, P = 0.098 and r = 0.349, P = 0.033 for left
and right ventral striatum, respectively). Therefore, these effects
were not baseline-dependent.
On the contrary, changes in sustained attention associated with
BPND % change in substantia nigra/ventral tegmental area were
dependent on baseline A’ scores, the correlations for this region no
longer being significant (r = 0.223, P = 0.142 for bilateral substan-
tia nigra/ventral tegmental area; r = 0.144, P = 0.228 and
r = 0.218, P = 0.129 for left and right substantia nigra/ventral teg-
mental area, respectively). Corroborating this finding, repeated
measures ANOVA revealed lower BPND % change in low com-
pared with high performers in substantia nigra/ventral tegmental
area (Fig. 9) [F(1,28) = 9.351, P = 0.005; F(1,28) = 5.46, P = 0.027
and F(1,28) = 5.2, P = 0.030 for bilateral, left and right substantia
nigra/ventral tegmental area, respectively], but not in any other
region.
Stepwise linear regression modelling to determine the relative
impact of methylphenidate-induced BPND changes across regions
and methylphenidate plasma levels on drug-induced A’ changes
confirmed the role of the right midbrain in predicting changes in
attentional performance [ = 0.39, P = 0.30; F(1,30) = 5.21, ad-
justed R2 = 0.12]. A further regression model revealed that base-
line performance levels on A’ predicted BPND changes specifically
in the left midbrain [ = 0.471, P50.01; F(1,30) = 8.57,
adjusted R2 = 0.20], confirming the above correlational results.
Baseline performance-dependent regional BPND
On placebo, low performers had reduced BPND in left pre-com-
missural dorsal caudate (Fig. 10A) [F(1,28) = 4.63, P = 0.04]. As
Figure 8 Regression lines representing the relationship between methylphenidate (MPH) effects on RVP A’ scores and 18F-fallypride BPND
% change in (A) right ventral striatum (VST) and (B) right substantia nigra/ventral tegmental area (SN/VTA). Correlation coefficients in
these regions were significantly different (z = 2.43, P5 0.001). Note the x-axis scales are different.
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Figure 9 BPND % change in substantia nigra/ventral tegmental
area for high and low performers. Low performers had
decreased BPND % change following methylphenidate (MPH)
(P = 0.007), suggesting that drug-induced increase in en-
dogenous dopamine in this region was smaller than for high
performers.
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shown in Fig. 10B, on methylphenidate this group difference was
no longer observed [F(1,28) = 2.97, P = 0.096].
Discussion
This study examined the neural basis of the attentional deficits
associated with ADHD and the mechanisms underpinning a
single therapeutic dose of methylphenidate through the applica-
tion of multi-modal state-of-the-art neuroimaging techniques.
Adult patients with ADHD as a group had marked deficits in sus-
tained attention and showed reduced grey matter volume in dis-
tributed frontostriatal and limbic circuits relative to control
subjects. No significant group differences in D2/D3 receptor avail-
ability were found; however, poor performance on the computer-
ized sustained attention task across both patient and control
groups was associated with low BPND values in the left caudate.
Methylphenidate increased dopamine levels across all striatal re-
gions as well as the midbrain similarly in patients with ADHD and
control subjects, thereby normalizing D2/D3 receptor availability in
low performers. The drug improved sustained attention in a base-
line-dependent manner independently from diagnosis. Subjects
performing poorly at baseline also had significantly smaller drug-
induced dopamine release in the midbrain. Collectively these novel
results suggest that deficits in sustained attention are associated
with both reduced D2/D3 receptor availability in the left caudate
on placebo and reduced dopamine release in the midbrain in re-
sponse to methylphenidate, and that these relationships hold irre-
spective of ADHD diagnosis.
Neural correlates of ADHD
The absence of overall group differences in 18F-fallypride binding
in this study may seem to be at variance with previous reports of
reduced 11C-raclopride binding in selected brain regions of the left
hemisphere in adult patients with ADHD compared with control
subjects (Volkow et al., 2007b, 2009). However, it is possible that
the apparent discrepancy can be resolved by the following con-
sideration: low performing subjects drawn from both ADHD and
control groups on the computerized test of sustained attention in
fact had significantly lower BPND (attributed to lower D2/D3 re-
ceptor availability) in the left pre-commissural caudate than high-
performing subjects, though independent of diagnosis. This result
is consistent with previous evidence implicating the left caudate in
inattentiveness, not only in patients with ADHD, but also in
healthy subjects (Schrimsher et al., 2002; Volkow et al., 2007a,
b, 2009) and is also congruent with reports that lesions in the left
caudate produce attentional deficits (Benke et al., 2003).
Our findings define a role for D2/D3 receptor availability in the
manifestation of attentional deficits that can be explained in the
light of the previously hypothesized continuum model of cognitive
deficits and underlying dopaminergic dysregulation associated with
ADHD (Sahakian and Robbins, 1977). Consistent with the model,
the attentional deficits observed in ADHD fall along a single
normal continuum extending into the healthy population, with
patients with ADHD predominantly representing the lower end
of the distribution. However, the lack of overall group differences
in 18F-fallypride binding argue against a primary nigro-striatal-
dependent dopamine dysfunction in adult ADHD. Thus, although
our data suggest that dopamine plays a key role in attention def-
icits, they also imply that dopaminergic deficits alone do not
account for an ADHD diagnosis. What is then different in
ADHD in neural terms?
Of course it is possible that such differences in dopamine func-
tion may exist within other regions not addressed here such as the
frontal cortex (e.g. Ernst et al., 1998, but see also Del Campo
et al., 2011a for discussion). However, the sensitivity of 18F-fall-
ypride to the methylphenidate dose administered in the current
design was arguably suboptimal for detecting robust changes in
dopamine levels in regions with low D2/D3 receptor density such
as the prefrontal cortex. A further possibility is that the central
noradrenergic system is selectively affected in ADHD. In support
of this hypothesis, atomoxetine, a selective noradrenergic reuptake
inhibitor, has been reported to be effective in the treatment of
ADHD and some of its associated cognitive deficits (Chamberlain
et al., 2007). Finally, it may also be argued that ADHD as
described in the DSM-IV encompasses an array of phenotypes
and underlying mechanisms too broad and heterogeneous to be
associated with a primary neurobiological dysfunction common to
all patients. The Research Domain Criteria project (RDoC) recently
launched by the National Institute of Mental Health, which
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Figure 10 BPND in left pre-commissural caudate in high and low
performers following (A) placebo and (B) methylphenidate
(MPH). Low performers had reduced BPND in left pre-commis-
sural caudate on placebo (P = 0.035), which was normalized by
methylphenidate.
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encourages the development of new ways of classifying psycho-
pathology based on dimensions of observable behaviour and
neurobiological measures, represents an important step forward
for future research which may help encapsulate the heterogeneity
in ADHD. However, it is striking that although no group differ-
ences were found in terms of dopamine activity in our study, the
same group of adult patients with ADHD had significant brain
tissue abnormalities in frontostriatal and limbic structures com-
pared with control subjects.
Methylphenidate-induced dopamine
increases: regional dependence and
therapeutic implications
Some of the present findings on effects of methylphenidate are
relevant to the more general understanding of stimulant drug
action in healthy humans, other than simply in patients with
ADHD. Thus, here we report, for the first time, that thera-
peutic doses of methylphenidate administered orally reduce 18F-
fallypride binding, which can be attributed to methylphenidate-
induced increases in synaptic dopamine levels. Effect sizes and
rank order of 18F-fallypride BPND % change across subregions of
the striatum and the midbrain were comparable with those docu-
mented following oral administration of amphetamine (Riccardi
et al., 2006a; Cropley et al., 2008) (Supplementary material),
the alternative first-line treatment for ADHD which also increases
catecholamine levels, albeit via different cellular mechanisms
(Faraone and Glatt, 2010). Consistent with previous reports, the
substantia nigra/ventral tegmental area showed high levels of
BPND % change, which were comparable to those observed in
sensorimotor striatum.
These findings replicate the preferential effect of methylphenid-
ate in the sensorimotor striatum when administered orally using
11C-raclopride binding (Clatworthy et al., 2009). The preferential
effect of oral methylphenidate and amphetamine on dorsal com-
pared to ventral regions of the striatum, however, is in contrast
with the well-replicated finding that intravenous amphetamine
leads to greater dopamine changes in ventral compared to
dorsal striatum (Drevets et al., 1999, 2001; Martinez et al.,
2003). Animal evidence suggests that the ability to increase dopa-
mine in ventral striatum, involved with reward circuitry, is a
common pharmacological effect underlying the reinforcing proper-
ties of virtually all drugs of abuse (Di Chiara and Imperato, 1988;
Bradberry et al., 2000). Consistent with these data, in healthy
humans, amphetamine-induced dopamine changes in ventral but
not dorsal striatum were found to predict hedonic responses
(Drevets et al., 2001; Leyton et al., 2002; Martinez et al., 2003).
The pattern of dopamine changes observed along the ventral–
dorsal gradient of the striatum following oral versus intravenous
administration of methylphenidate and amphetamine may be ex-
plained in light of the different pharmacokinetics associated with
each route of drug administration. Whereas oral methylphenidate
penetrates the brain only slowly, peaking 60–90 min after admin-
istration, intravenous methylphenidate rapidly enters the brain,
peaking in 515 min. The large and abrupt dopamine increase
after intravenous administration is perceived as reinforcing, an
effect that appears to be reduced when the increase in dopamine
is slow and progressive (Volkow, 2006).
Overall, the differences in regional patterns of methylphenidate-
induced dopamine increase following oral versus intravenous
methylphenidate administration suggest that the mechanisms
underlying the effects of the drug to improve attention differ
from those mediating its reinforcing actions.
Baseline performance-dependent effects
of methylphenidate
Methylphenidate significantly improved sustained attention in a
baseline-dependent manner in low performers from both groups.
Although the lack of methylphenidate effects on attention in high
performers was possibly due to ceiling effects, this does not under-
mine the key finding that the drug is capable of improving sus-
tained attention in low-performing individuals, regardless of
ADHD diagnosis. This result adds to previous evidence demon-
strating equivalence of behavioural stimulant effects in individuals
with and without ADHD (Rapoport et al., 1978, 1980), supporting
a dimensional model of attentional deficits and underlying cate-
cholaminergic mechanisms of ADHD which extends into the
healthy population. It is also consistent with a growing literature
documenting baseline performance-dependent effects of stimu-
lants and related drugs, which have been explained by a hypothe-
sized inverted U-shaped function, whereby optimal catecholamine
levels determine optimal performance, and levels along the curve
at either side of the optimum are associated with impaired per-
formance (Robbins and Sahakian, 1979; Naylor et al., 1985;
Williams and Goldman-Rakic, 1995; Kimberg et al., 1997;
Arnsten and Goldman-Rakic, 1998; Rogers et al., 1999; Mattay
et al., 2000, 2003; Tipper et al., 2005; Finke et al., 2010).
Inverted U-shaped functions as invoked here accurately describe
the dose-response relationships often observed in psychophar-
macological studies of cognition (Dews, 1958; Sahakian and
Robbins, 1977; Cools and Robbins, 2004; Robbins, 2010). Our
data do not allow drawing conclusions on the declining portion
of the hypothesized function. Further research is needed to test
the full dose-response curve of methylphenidate, which would
require higher doses than the one used here.
A central finding of this study was that the drug-induced
changes in performance correlated with changes in midbrain
dopamine levels (Fig. 11), a result that remained unchanged
after excluding ceiling performers. Changes in midbrain dopamine
levels mirrored the behavioural baseline-dependent effect: low
performers had reduced methylphenidate-induced BPND reductions
in the midbrain compared with high performers, with smaller
dopamine changes being associated with greater improvements
on the sustained attention task. These robust neurobiological cor-
relates argue against the behavioural baseline-dependent effects
resulting simply from a statistical regression towards the mean.
These findings suggest that the effects of methylphenidate on
midbrain dopamine levels play a hitherto unknown role in the
modulation of attention. A further likely mechanism by which me-
thylphenidate improved sustained attention in low performers is
the observed normalization of dopamine levels in the left caudate.
An 18F-fallypride PET study of attention Brain 2013: 136; 3252–3270 | 3263
Midbrain mechanisms underlying
therapeutic effects of methylphenidate
Methylphenidate-induced dopamine changes in substantia nigra/
ventral tegmental area were negatively related to dopamine
changes in ventral striatum but not associative striatum or sensori-
motor striatum. These results may reflect regional differences in
the response of midbrain dopamine neurons following methyl-
phenidate administration. Dopamine neurons located in the mid-
brain receive -aminobutyric acid (GABA)-ergic projections from
the same striatal subregion they project to through reciprocal con-
nections, giving rise to topographically organized striato-nigro-
striatal circuits (Haber et al., 2000). Additionally, this system
provides non-reciprocal connections, facilitating dopamine trans-
mission along a feed–forward spiral starting in the ventral striatum
and finishing in the sensorimotor striatum, whose projections to
the midbrain are confined to the regions from which it receives its
dopamine input (Haber et al., 2000) (Fig. 12A). GABAergic neu-
rons descending from the striatum to the midbrain can inhibit or
stimulate dopamine cell firing depending on whether they contact
dopamine neurons or GABAergic interneurons. After administra-
tion of psychostimulants (Bunney and Achajanian, 1976), including
methylphenidate (Shi et al., 2004), the inhibitory effect prevails,
leading to decreased responsiveness in dopaminergic neurons
(Fig. 12B).
We hypothesize that the inverse relationship in dopamine re-
lease between substantia nigra/ventral tegmental area and ventral
striatum but not associative striatum or sensorimotor striatum fol-
lowing methylphenidate reflects the asymmetrical nigro-striatal
projection pattern. Ventral striatum is the only striatal region
whose dopamine input is unaffected by non-reciprocal connec-
tions, its dopaminergic input thus being regulated to a greater
extent by synthesis- and release-regulating midbrain dopamine
autoreceptors. The observed inverse correlation may thus reflect
the inhibitory influences exerted by midbrain dopamine neurons to
regulate dopamine levels in ventral striatum. This inverse relation-
ship did not hold for associative striatum and sensorimotor
striatum, which can be explained by the fact that, via the afore-
mentioned feed–forward spiralling connections, associative stri-
atum receives additional inhibitory influences from ventral
striatum and sensorimotor striatum from both ventral striatum
and associative striatum. These findings possibly constitute the
first direct evidence in humans supporting the notion that the
doses used clinically to treat ADHD exert their therapeutic actions
through presynaptic mechanisms. A key finding of this study is
that midbrain dopamine autoreceptor regulation was reduced in
low performers, as evidenced by the significantly smaller methyl-
phenidate-induced increases in midbrain dopamine levels observed
in low compared to high performers (Fig. 12C).
How are the changes in midbrain dopamine receptor availability
related to the attention-enhancing effects of methylphenidate,
whether in patients with ADHD or healthy control subjects?
A plausible explanation is provided by the classical model of cat-
echolamine neurotransmission regulation and psychostimulant
action postulated by Grace (1991, 2001). According to this
model, the amplitude of the phasic dopamine response is dynamic-
ally regulated by the influence of corticostriatal activity through the
modulation of tonic dopamine levels. Low tonic dopamine activity is
associated with abnormally high phasic dopamine responses, result-
ing in distractibility and impaired attention. Stimulants enhance tonic
catecholamine levels, thereby increasing postsynaptic catecholamine
receptor stimulation but also triggering negative feedback mechan-
isms through stimulation of dopamine autoreceptors. As a result,
dopamine synthesis is reduced, dopamine neuron firing inhibited
and subsequent phasic (spike-dependent) transmitter release
reduced.
The idea that the clinical effects of stimulants are mediated by the
ability of small increases in extracellular dopamine to produce a net
decrease in phasic catecholamine release by the selective activation
of dopamine autoreceptors (following an increase in tonic dopamine
levels) (Solanto, 1984, 1998; Seeman and Madras, 1998) is sup-
ported by studies showing reduction in behavioural activity levels in
children with ADHD following low doses of dopamine agonists in
the range presumed to stimulate autoreceptors (Solanto, 1986) and
from neurocomputational models (Oades et al., 1985; Sawaguchi
et al., 1988; Daniel et al., 1991; Servan-Schreiber et al., 1998; Li
et al., 2001; MacDonald et al., 2009). It can thus be concluded that
stimulant-induced increases in endogenous midbrain dopamine in
the presence of reduced tonic striatal dopamine levels observed
in low performers may improve the signal-to-noise ratio, thereby
normalizing the system to approximate that characterizing high
performing subjects.
Strengths and limitations
In an attempt to identify putative biomarkers of ADHD, we used,
for the first time, an interdisciplinary approach encompassing both
PET and MRI in combination with neuropsychopharmacological
assessment which allowed characterization of the disorder at
clinical, cognitive, neurochemical and neuroanatomical levels.
The current paper focused on the neuropsychopharmacological
Figure 11 Regression line representing the relationship be-
tween methylphenidate (MPH) effects on sustained attention
and on 18F-fallypride BPND in the midbrain (r = 0.502; P = 0.002,
two-tailed). SN/VTA = substantia nigra/ventral tegmental area.
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findings; a companion paper will address in more detail grey and
white matter tissue in relation to the behavioural changes.
An important innovation of this study relative to previous ADHD
PET studies was the use of high resolution co-registered MRI
images to help localize the PET signal. This was crucial to allow
segmentation of the striatum into its functional subregions, known
to have different tracer uptake due to heterogeneous D2/D3
receptor density (Del Campo et al., 2011b).
A further strength was the experimental design, (double-blind,
randomized, cross-over) which differs from the fixed design (pla-
cebo first, followed by drug) used in previous studies investigating
the effects of methylphenidate in ADHD (Rosa-Neto et al., 2005;
Volkow et al., 2007b). It might be argued that placebo is not
equivalent to a null condition, and thus the comparison between
studies using placebo as a control condition with those in which
baseline measurements are acquired might be suboptimal. Indeed,
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Figure 12 Schematic model of dopamine activity along striato-nigro-striatal circuits at baseline (A) and after oral methylphenidate (MPH)
in high (B) and low performers (C). Ascending arrows represent projections from dopamine (DA) neurons located in the substantia nigra
(SN)/ventral tegmental area (VTA) to the striatum and descending arrows represent GABA-ergic projections from the striatum to the
substantia nigra/ventral tegmental area. Different colours represent different striatal functional circuits (red = limbic, green = associative,
blue = sensorimotor). Methylphenidate administration (B) increased postsynaptic catecholamine stimulation (solid lines), leading to in-
hibition of dopamine neuron firing (dashed lines) by activation of synthesis- and release-regulating dopamine autoreceptors. It is sug-
gested that the level of responsivity of dopamine neurons and subsequent striato-nigro-striatal neuromodulation following
methylphenidate administration was dependent on baseline dopamine activity in the striatum. Adapted from Haber et al. (2000) and
Martinez et al. (2003). CAU = caudate PUT = putamen; VST = ventral striatum.
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PET evidence has shown that sensitization to amphetamine in
humans leads to carry-over effects in subsequent sessions when
placebo is administered (Boileau et al., 2007). These findings imply
that placebo administered in the session subsequent to stimulant
treatment can potentially reduce the power to detect true stimu-
lant effects and identify neurobiological markers in psychiatric
populations. However, fixed designs entail order effects, thereby
introducing the confounding effect of drug anticipation. PET evi-
dence suggests that anticipation of stimulants such as caffeine can
induce dopaminergic responses in humans (Kaasinen et al., 2004).
To address this issue, placebo 18F-fallypride BPND values were
compared with 18F-fallypride BPND estimates documented by
other groups in the same regions of interest at baseline in fixed
designs (Riccardi et al., 2006a; Cropley et al., 2008; Slifstein et al.,
2010) (Supplementary material). Values were largely comparable
in terms of both magnitude and rank order, suggesting that the
regional BPND values reported here following placebo administra-
tion were within the expected baseline ranges. One way future
research might help to disentangle undesired effects of drug-order
and stimulant carry-over effects is through implementation of a
double-blind randomized design with parallel groups, as used by
Aalto et al. (2009) where each subject underwent two scans; the
first at baseline and the second after administration of either a
psychostimulant or placebo. However, there is no evidence to
suggest that our design produced anomalous results.
A caveat of dopamine receptor imaging technique as the one
reported here is that receptor availability and dopamine release are
inferred from estimates of BPND, which is a combined measure of
receptor availability and radioligand affinity. Consequently, we
were not able to assess whether dynamics such as receptor intern-
alization (Laruelle, 2000) or changes in the affinity of D2/D3
receptors for dopamine and/or fallypride were implicated
(Laruelle, 2000; Gjedde et al., 2005). In the absence of informa-
tion regarding levels of endogenous dopamine, it was not possible
to determine to what extent D2/D3 receptor availability reflected
receptor density or basal occupancy. Moreover, this technique did
not allow a distinction of the proportion of different D2/D3 recep-
tor types (synaptic versus extra-synaptic, post versus
presynaptic) or their state of affinity for dopamine. It is important
to note also that the slow kinetics of 18F-fallypride necessitated a
long acquisition period (3.15 h) and thus did not allow us to dif-
ferentiate tonic from phasic dopamine activity in the midbrain,
which can only be inferred.
A further methodological aspect that merits discussion concerns
partial volume effects, defined as the loss in spatial resolution re-
sulting in spill-over of image signal to and from adjacent struc-
tures. Specifically, partial volume effects are to be considered as a
potential confounding factor of radiotracer uptake when the struc-
tures under study are small and/or when adjacent structures have
high signal contrast. 18F-fallypride PET imaging of the striatum
satisfies both these criteria and hence partial volume effects are
theoretically an issue of concern in this study. Moreover, our find-
ing of reduced grey matter volume in the putamen in patients
with ADHD compared with control subjects implies that partial
volume effects may have had a differential effect on sub-striatal
BPND estimation in patients and control subjects, potentially mask-
ing group differences in regional D2/D3 receptor availability. In
order to rule this out, an additional set of analyses was carried
out to estimate partial volume error using an in-house implemen-
tation of a well-validated method (Rousset et al., 1998). A de-
tailed account of the methodology used and the results can be
found in the Supplementary material. Importantly, signal recovery
due to partial volume effect was similar in patients with ADHD
and control subjects, independently from brain region and experi-
mental condition, and thus it can be concluded that the grey
matter changes observed in patients did not confound the PET
results here reported.
Finally, the medication history of the patients also needs discuss-
ing, as half of the patients in the current study had been previ-
ously exposed to ADHD medication. Although this study was not
designed to resolve the question of whether patients with ADHD
with a history of pharmacological treatment have different D2/D3
receptor availability compared to medication-naı¨ve patients, we
did not find any differences in PET measurements between pa-
tients with previous exposure to ADHD medication and medica-
tion-naı¨ve patients (all P4 0.05). Importantly, to ensure complete
washout at the time of scanning among patients under current
treatment, compliance with treatment discontinuation 3 days
before each PET scan was verified through urine screening.
Moreover, medication status was controlled for in all repeated
measures ANOVAs. There is a lack of clarity regarding chronic
effects of ADHD medication, with different studies reporting
contradicting results with regard to its impact on dopaminergic
markers (Gill et al., 2012; Volkow et al., 2012). Further research
and suitable study designs are needed to fully characterize the
consequences of long-term pharmacological ADHD treatment
both at the behavioural and at the neurobiological levels.
Conclusion
The present findings query the precise role of dopamine in the
pathophysiology in adult ADHD. Although our findings are con-
sistent with the modulation of attention by nigro-striatal dopamine
and with poor attention being a key deficit in the clinical profile of
ADHD, our data also suggest that dopamine dysregulation per se
is unlikely to be the primary cause underlying ADHD pathology in
adults. This conclusion is reinforced by evidence of structural brain
changes in the same set of patients with adult ADHD.
We also conclude that a more precise explanation of the behav-
ioural effects of psychostimulant treatment in both patients with
ADHD and healthy control subjects can be derived from the com-
bination of (i) dose and time course of methylphenidate actions; (ii)
level of responsivity of the dopamine system determined by tonic
dopamine levels; and (iii) baseline level of performance, possibly re-
flecting basal dopamine function in the striatum. The findings of
reduced methylphenidate-induced midbrain dopamine increases
and improved sustained attention in low performers (mostly patients
with ADHD) implicate a hitherto neglected role of midbrain dopa-
mine in the mediation of therapeutic effects of methylphenidate.
We have shown the considerable potential of combining the
complementary strengths of structural MRI and neuroreceptor
PET imaging in identifying and characterizing cognitive
3266 | Brain 2013: 136; 3252–3270 N. del Campo et al.
endophenotypes of ADHD, which may help our understanding of
the diagnosis, prognosis and treatment of ADHD.
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